“US Generics Industry will be worth around US$ 72 Billion in 2018, owing to Ongoing Patent Cliff, Inclining healthcare expenditure, Rising disposable incomes, and the Emergence of Obamacare”, says RNCOS.
Noida, UP -- (SBWIRE) -- 04/03/2015 -- According to a new research report by RNCOS entitled, "US Generic Drug Market Outlook 2018", the US represents the world's largest pharmaceutical markets with highest prescription sales. It is amongst the most attractive prescription drug markets and has caught the attention of several manufacturers globally, as evident from the launch of numerous generic equivalents of the branded products. Factors such as continuing patent expiration, increasing healthcare expenditure, revision of the Obamacare healthcare bill, rising disposable incomes, reduced prices of medications and rising ageing population, etc., have been driving the US Generics market, which accounts for 45% of the global Generics industry.
Moreover, with the implementation of Hatch-Waxman Act, the Generics industry has opened up for the entry of new products. Several foreign firms have expanded their business in the US market either through mergers & acquisitions or by independently launching Generic equivalents through their subsidiaries. Actavis, Sandoz, Teva pharma, Mylan, Lupin, Pfizer, etc. are some of the prominent players in the US Generics market. These players have been competing on a first-to-launch basis, launching generic drugs as soon as branded drugs lose patent. RNCOS estimates that the Generic market, which was around US$ 43.5 Billion in 2013, will grow at a CAGR of 11% in the next five years to become a US$ 72 Billion industry.
Research Analysis & Highlights
The report is spread in over 100 pages and provides an in-depth research and rational analysis of the current status and future prospect of the US Generics industry. The report provides a clear picture of Generics market, its growth, and drivers & challenges pertaining to it. In addition to this, the study further highlights emerging trends and developments which have been occurring in the US over the years, market potential of Generics in key therapeutic segments, competitive landscape and regulatory scenario, among other pointers. It also provides valuable information to pharmaceutical and generic drug companies and investors looking to enter this market. Facts and figures regarding market size, growth, share, regulatory environment and trends in technology development have been thoroughly analyzed in the report to provide clients a comprehensive overview of the market.
Some of the key findings of the report are:
- Growth Drivers such as Inclining Healthcare expenditure, Rising Disposable Incomes, Growing Ageing Population and Mergers & Acquisitions
- Market Segmentation by Branded and Generics
- Patent expiry of blockbuster drugs in various therapeutic segments such as Oncology, Respiratory, Mental Health, and Obesity, etc
- Leading Players and their share in US Generics market
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM731.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.